Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-FXS: Sulindac and Gaboxadol in Fragile X Syndrome
NCT04823052Phase 2Withdrawn
- Sponsor
- Healx
- Start
- May 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of sulindac, gaboxadol in Fragile X syndrome (FXS), sponsored by Healx. Planned start May 2022; status: withdrawn.
02
Drugs
sulindacgaboxadol
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT04823052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04823052.